You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD73

Showing 1 - 25 of 2,542
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor Trial (HLX23)

Withdrawn
  • Advanced Solid Tumor
  • Los Angeles, California
  • +5 more
Jan 13, 2023

Arterial Calcification, CD73 Deficiency Trial run by the NHLBI (Etidronate, MRI Scan)

Completed
Has Results
  • Arterial Calcification
  • CD73 Deficiency
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 9, 2022

Advanced Solid Tumor Trial in Beijing (CD73 Antigen)

Recruiting
  • Advanced Solid Tumor
  • CD73 Antigen
  • Beijing, China
    Beijing Cancer Hospital
Jul 10, 2023

Lung Cancer Circulating Tumor Cells

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Sample
  • Nice, France
    CHU de Nice
Dec 5, 2022

Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Trial in Boston (AGEN1423,

Not yet recruiting
  • Advanced Pancreatic Ductal Adenocarcinoma
  • +2 more
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Nov 18, 2022

Advanced Cancer Trial in Australia, United Kingdom, United States (LY3475070, Pembrolizumab)

Completed
  • Advanced Cancer
  • Denver, Colorado
  • +11 more
Nov 24, 2022

Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer Trial in Marseille (IPH5301 ALONE OR IN COMBINATION

Recruiting
  • Metastatic Cancer
  • +8 more
  • IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
  • Marseille, France
    Institut Paoli Calmettes
Feb 23, 2022

Solid Tumor Trial in Jinan (IBI325 + sintilimab, IBI325)

Active, not recruiting
  • Solid Tumor
  • Jinan, Shandong, China
    Shandong Province Cancer Hospital
Oct 10, 2022

Solid Tumor Trial in Shanghai, Tianjin (AK119)

Recruiting
  • Solid Tumor
  • Shanghai, China
  • +1 more
Apr 18, 2022

Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8 Trial

Recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +5 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Advanced or Metastatic Solid Tumors Trial in Australia (AK119, AK104)

Active, not recruiting
  • Advanced or Metastatic Solid Tumors
  • AK119
  • AK104
  • Blacktown, New South Wales, Australia
  • +4 more
Jan 5, 2023

Solid Tumor, Adult Trial in Boston, Canton, Houston (HB0045 Drug Product)

Not yet recruiting
  • Solid Tumor, Adult
  • HB0045 Drug Product
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Solid Tumor, Adult Trial in Boston, Canton, Houston (HB0045 Drug Product)

Not yet recruiting
  • Solid Tumor, Adult
  • HB0045 Drug Product
  • Boston, Massachusetts
  • +2 more
Jul 5, 2023

Solid Tumor Trial (JAB-BX102 (anti-CD73 mAb), pembrolizumab (anti-PD-1 mAb))

Not yet recruiting
  • Solid Tumor
  • JAB-BX102 (anti-CD73 monoclonal antibody)
  • pembrolizumab (anti-PD-1 monoclonal antibody)
  • (no location specified)
Jul 19, 2022

Solid Tumor Trial in Jinan (IBI325+Sintilimab)

Not yet recruiting
  • Solid Tumor
  • Jinan, Shandong, China
    Shandong Province Cancer Hospital
Feb 17, 2022

Coronavirus Disease 2019 (COVID-19) Trial in Christchurch (AK119, Placebo)

Completed
  • Coronavirus Disease 2019 (COVID-19)
  • Christchurch, New Zealand
    Christchurch Clinical Studies Trust
Oct 15, 2021

Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)

Recruiting
  • Advanced Solid Tumor
  • +18 more
  • PT199
  • Anti-PD-1 monoclonal antibody
  • Huntersville, North Carolina
  • +2 more
Aug 10, 2022

Metastatic Cancer, Solid Tumor Trial in Canada, United States (Sym021, Sym024)

Recruiting
  • Metastatic Cancer
  • Solid Tumor
  • Grand Rapids, Michigan
  • +3 more
Dec 16, 2021

Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma Trial in Houston (Durvalumab,

Recruiting
  • Metastatic Angiosarcoma
  • +7 more
  • Durvalumab
  • Oleclumab
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2021

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma Trial in Los Angeles

Not yet recruiting
  • Borderline Resectable Pancreatic Adenocarcinoma
  • Locally Advanced Pancreatic Ductal Adenocarcinoma
  • Biospecimen Collection
  • +9 more
  • Los Angeles, California
    Yonemoto,Lisa
Jan 13, 2023

NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +12 more
  • Tucson, Arizona
  • +26 more
Aug 1, 2022

Pancreatic Ductal Adenocarcinoma Trial in New York (Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Stereotactic body radiotherapy (SBRT)
  • +4 more
  • New York, New York
    Columbia University Irving Medical Center
Sep 15, 2023

CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis

Completed
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Multi-parametric Flow Cytometry analysis on patients and healthy donors samples
  • Pierre-Bénite, France
    Service de Rhumatologie, Centre Hospitalier Lyon-Sud (HCL)
May 15, 2019

Metastatic Triple-negative Breast Cancer Trial in Italy (Tissue Immune Profile)

Recruiting
  • Metastatic Triple-negative Breast Cancer
  • Tissue Immune Profile
  • Prato, FI, Italy
  • +6 more
Apr 14, 2023

Triple Negative Breast Cancer Trial in Belgium, France (Paclitaxel, Carboplatin, MEDI4736)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Brussels, Belgium
  • +17 more
Feb 28, 2022